Sales for Brivaracetam in the Epilepsy Market

GlobalData expects UCB to launch brivaracetam in the US and EU in 2015. We estimate that 2022 sales of brivaracetam will reach $582.8m across these markets. Key factors affecting the uptake of brivaracetam will include:

- A crowded marketplace, which currently comprises more than 20 anti-epileptic drugs (AEDs), many of which are available in generic form, resulting in individual drugs struggling to distinguish themselves.
- Initially will only target refractory partial seizure patients who comprise only a fraction of the market.
- Brivaracetam may have higher potency and broader activity than its predecessor making it a strong competitor for Keppra’s (levetiracetam) market share.
- “Me-too” status means brivaracetam will have to directly compete with the market leader Keppra which is available in inexpensive generics.

What Do the Physicians Think?

- Overall physicians expressed a need for more AEDs and favorable opinions of those in pipeline development.

  “Among intractable epilepsy patients, any drug that helps treat an additional segment of them will be used, and because we don’t have a basis for using one or another, if it’s attractive, it will be used more.”

  [US] key opinion leader, November 2012
“Brivaracetam is an interesting concept because it’s supposed to be “Super Keppra,” the follow-on from Keppra. The Phase II studies were very promising, but I think the Phase III were a bit of a disappointment; there might be some methodological issues in terms of some patient selection issues that they have come across. But I think that’s one of the more interesting of the new drugs that I’m really wanting to see in clinical practice, particularly if, as the Phase II studies suggested, that some patients who haven’t responded to levetiracetam are responders to this drug. So, I think that that’s going to be one drug to watch.”

[EU] key opinion leader, November 2012

• In the future, physicians would like to see distinct new classes of AEDs that target different mechanisms, rather than more of the same drugs that currently dominate the market.

“Do we need the sixth or seventh sodium blocker? Do we need the tenth calcium channel modulator? I think we need new drugs, but more than that, I think we need new classes of drugs which address things differently.”

[EU] key opinion leader, October 2012

“If you ask me, my wish list would be disease-modifying drugs that you could use once or twice, once you determine that the person has a tendency for unprovoked seizures, and that would stop the process.”

[EU] key opinion leader, November 2012

• Physicians believe that a better understanding of the disease mechanisms in epilepsy will be crucial to developing more effective treatments.

“I would not discourage the development of drugs, but I think we need to change the paradigm. But to change the paradigm, we need to understand things better, so we need a lot of basic research.”

[EU] key opinion leader, November 2012

• However, with more than 20 existing AEDs, new ones currently entering the market, and more to come in the future, physicians are unsure of how all these drugs will fit in the treatment landscape, and lack a way to differentiate between them, particularly in terms of efficacy. Also, there are no predictive tools that would guide the choice of treatment from patient to patient.

“We have about 25 AEDs for focal (partial) epilepsy, but which one to choose? Upfront, it’s tough to say because we don’t have any tests to say, ‘this is the lamotrigine patient and this is the levetiracetam patient’.”

[EU] key opinion leader, October 2012

• However, with more than 20 existing AEDs, new ones currently entering the market, and more to come in the future, physicians are unsure of how all these drugs will fit in the treatment landscape, and lack a way to differentiate between them, particularly in terms of efficacy. Also, there are no predictive tools that would guide the choice of treatment from patient to patient.

“We have about 25 AEDs for focal (partial) epilepsy, but which one to choose? Upfront, it’s tough to say because we don’t have any tests to say, ‘this is the lamotrigine patient and this is the levetiracetam patient’.”

[EU] key opinion leader, October 2012
1 **Table of Contents**

1 Table of Contents ........................................................................................................ 4

1.1 List of Tables ........................................................................................................... 7

1.2 List of Figures .......................................................................................................... 8

2 Introduction .................................................................................................................. 9

2.1 Catalyst .................................................................................................................. 9

2.2 Related Reports ..................................................................................................... 10

3 Disease Overview ....................................................................................................... 12

3.1 Classification of Seizures ..................................................................................... 14

3.2 Etiology and Pathophysiology ............................................................................. 15

3.2.1 Etiology ........................................................................................................... 15

3.2.2 Pathophysiology ............................................................................................. 18

3.2.3 Prognosis ........................................................................................................ 23

3.2.4 Quality of Life ................................................................................................. 24

4 Disease Management ................................................................................................. 25

4.1 Diagnosis ............................................................................................................... 25

4.2 Treatment Guidelines .......................................................................................... 26

4.3 Clinical Practice .................................................................................................... 27

5 Competitive Assessment ............................................................................................. 33

5.1 Overview ............................................................................................................... 33

5.2 Strategic Competitor Assessment ....................................................................... 35

6 Opportunity and Unmet Need .................................................................................. 38

6.1 Overview ............................................................................................................... 38

6.2 Unmet Needs ......................................................................................................... 39

6.2.1 Refractory Epilepsy ....................................................................................... 39

6.2.2 Safety/Side Effect Profiles ............................................................................ 39

6.2.3 Curative/Disease-Modifying Agents ............................................................ 40

6.2.4 Predictive Tools and Need for More Directed Treatments ....................... 41
# Table of Contents

6.2.5 Improved Preclinical Models and Clinical Trial Paradigms .................................................. 41
6.2.6 Treatment Gap.................................................................................................................. 42
6.3 Unmet Needs Gap Analysis....................................................................................................... 43
6.4 Opportunities.......................................................................................................................... 44
6.4.1 Disease-Modifying Agents.................................................................................................. 44
6.4.2 Improved Preclinical Models and Clinical Trial Paradigms .................................................. 44
6.4.3 Treatment Gap.................................................................................................................. 44

7 Pipeline Assessment.................................................................................................................... 45
7.1 Overview.................................................................................................................................. 45
7.2 Strategic Pipeline Assessment.................................................................................................... 45
7.3 Pipeline by Phases of Development............................................................................................ 46
  7.3.1 Phase III Pipeline............................................................................................................... 46
  7.3.2 Phase III Pipeline – Reformulations/New Delivery Systems.................................................. 46
  7.3.3 Phase IIb Pipeline............................................................................................................. 47
  7.3.4 Phase II Pipeline............................................................................................................... 47
  7.3.5 Phase I Pipeline................................................................................................................. 48
  7.3.6 Preclinical Pipeline.......................................................................................................... 49
  7.3.7 Discovery Pipeline............................................................................................................ 50
7.4 Pipeline by Mechanism of Action................................................................................................. 50
7.5 Promising Drugs in Clinical Development.................................................................................. 52

8 Brivaracetam................................................................................................................................ 53
  8.1 Overview............................................................................................................................... 53
  8.2 Efficacy.................................................................................................................................. 53
  8.3 Safety..................................................................................................................................... 54
  8.4 Dosing and Formulation.......................................................................................................... 54
  8.5 Potential Clinical Positioning.................................................................................................... 54
  8.6 Potential Commercial Positioning............................................................................................. 54
  8.7 Pricing and Reimbursement...................................................................................................... 55
## Table of Contents

8.8 SWOT Analysis ............................................................................................................. 55  
8.9 Forecast ......................................................................................................................... 55  

9 Appendix ............................................................................................................................ 57  
  9.1 Bibliography .................................................................................................................. 57  
  9.2 Abbreviations ................................................................................................................. 59  
  9.3 Methodology .................................................................................................................. 61  
  9.4 Forecasting Methodology ............................................................................................... 61  
    9.4.1 Prevalent Epilepsy Patients ....................................................................................... 61  
    9.4.2 Percent Drug-Treated Patients ............................................................................... 62  
    9.4.3 General Pricing Assumptions ................................................................................... 62  
    9.4.4 Generic Erosion ....................................................................................................... 63  
    9.4.5 Pricing of Pipeline Agents ....................................................................................... 63  
  9.5 Physicians and Specialists Included in this Study ......................................................... 64  
  9.6 Primary Research - Prescriber Survey ......................................................................... 65  
  9.7 About the Authors ......................................................................................................... 66  
    9.7.1 Authors .................................................................................................................... 66  
    9.7.2 Global Head of Healthcare ..................................................................................... 67  
  9.8 About GlobalData ......................................................................................................... 68  
  9.9 Contact Us ..................................................................................................................... 68  
  9.10 Disclaimer .................................................................................................................... 68
1.1 List of Tables

Table 1: Epilepsy Syndromes by Age at Onset (2009 ILAE Classification) ........................................... 13
Table 2: Classification of Seizures ............................................................................................................. 14
Table 3: Etiology of Epilepsy According to Age ..................................................................................... 15
Table 4: Etiology of Partial Seizures ........................................................................................................ 16
Table 5: Etiology of Generalized Seizures ............................................................................................... 17
Table 6: Some of the Genes Involved in Epilepsy ................................................................................ 22
Table 7: Summary of Diagnostic Tools for Epilepsy ............................................................................. 25
Table 8: Treatment Guidelines for Epilepsy ......................................................................................... 26
Table 9: AED Options by Seizure Type .................................................................................................... 30
Table 10: Top Three AEDs Prescribed for Epilepsy by Market ............................................................. 31
Table 11: Types of Epilepsy Surgery ...................................................................................................... 32
Table 12: Leading Treatments for Epilepsy, 2012 ................................................................................. 37
Table 13: Overall Unmet Needs – Current Level of Attainment ........................................................... 38
Table 14: Clinical Unmet Needs – Gap Analysis, 2012 ...................................................................... 43
Table 15: Epilepsy – Phase III Pipeline, 2012 ....................................................................................... 46
Table 16: Epilepsy – Phase III Pipeline (Reformulations), 2012 ............................................................ 46
Table 17: Epilepsy – Phase IIb Pipeline, 2012 ....................................................................................... 47
Table 18: Epilepsy – Phase II Pipeline, 2012 ....................................................................................... 47
Table 19: Epilepsy – Phase I Pipeline, 2012 ......................................................................................... 48
Table 20: Epilepsy – Preclinical Pipeline, 2012 ................................................................................... 49
Table 21: Epilepsy - Discovery Pipeline, 2012 .................................................................................... 50
Table 22: Comparison of MOA of Drugs in Development for Epilepsy, 2012 ................................. 51
Table 23: Epilepsy – Promising Drugs in Clinical Development .......................................................... 52
Table 24: Product Profile – Brivaracetam ............................................................................................... 53
Table 25: Brivaracetam SWOT Analysis, 2012 ..................................................................................... 55
Table 26: Global Sales Forecasts ($m) for Brivaracetam, 2012–2022 .................................................... 56
Table 27: Physicians Surveyed, By Country ......................................................................................... 65
1.2 List of Figures

Figure 1: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation19
Figure 2: Mechanisms of Action of AEDs at the Synapse ......................................................... 21
Figure 3: AED Selection Based on Comorbidity ........................................................................29
Figure 4: Epilepsy – Pipeline by MOA, 2012 ........................................................................... 51
Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Epilepsy, 2012–2022......52
2 Introduction

2.1 Catalyst

The epilepsy market has been very dynamic since 2008, with several of the market-leading drugs losing patent protection and experiencing steep sales declines, particularly in the United States, including:

- UCB’s Keppra (levetiracetam) (US patent expiry in 2008)
- GlaxoSmithKline’s (GSK’s) Lamictal (lamotrigine) (US patent expiry in 2008)

However, the decline in global sales of these products was buffered by their recent introduction into the Japanese market, as well as by a slower-than-expected uptake of generics for Keppra in Europe. Both of these former blockbuster drugs have also since been introduced to the market as extended-release formulations that hold exclusivity from generic competition during the forecast period. Levetiracetam (Keppra, Keppra XR, and generics) and lamotrigine (Lamictal, Lamictal XR, and generics) are predicted to remain key players in the clinical arena through the end of the forecast period in 2022, but will face stiff competition in market share from multiple new market entrants.

Since 2008, the epilepsy drug market has seen the approval and market entry of several major products, including:

- Eisai’s Banzel/Inovelon (rufinamide)
- UCB’s Vimpat (lacosamide)

And within the past two years:

- GSK’s Trobalt/Potiga (retigabine/ezogabine) – launched in the EU in 2012; approved in the US in 2011
- Eisai’s Fycompa (perampanel) – launched in the EU in 2012; approved in the US in October 2012

Of these new market entrants, Vimpat has experienced the most rapid uptake, providing competition for other sodium channel blockers, which represent the mainstay of epilepsy treatments in terms of mechanism of action (MOA). However, it is set to face patent expiry as soon as 2014, allowing the emergence of lacosamide generics, which will erode Vimpat sales. However, lacosamide as a whole (both Vimpat and generics) will continue gaining in market share during the forecast period, even after patent expiration.
Trobalt/Potiga, which is a potassium channel modulator; and Fycompa, which is an aminohydroxymethylisoxazole propionic acid (AMPA) receptor antagonist, are both new market entrants with novel first-in-class MOAs that offer patients, especially refractory patients, an alternative to the sodium and calcium channel blockers that have dominated the epilepsy treatment market in recent decades. Their safety and efficacy profiles, once tested in clinical practice, will determine their clinical position in the future treatment landscape and their significance as competitive market players.

The drivers for market growth will include the introduction of the newer drugs into the Asian market, particularly in Japan. India and China will also contribute to market growth as their populations obtain increasing access to epilepsy pharmacotherapy. The challenges will be the crowded marketplace, which currently comprises more than 20 antiepileptic drugs (AEDs), with individual drugs struggling to distinguish themselves, particularly in terms of efficacy.

2.2 Related Reports

- GlobalData (2013). Epilepsy – United States Drug Forecast and Market Analysis to 2022. GDHC1038CFR.
- GlobalData (2013). Epilepsy – United Kingdom Drug Forecast and Market Analysis to 2022. GDHC1043CFR.
- GlobalData (2013). Epilepsy – France Drug Forecast and Market Analysis to 2022. GDHC1039CFR.
- GlobalData (2013). Epilepsy – Germany Drug Forecast and Market Analysis to 2022. GDHC1040CFR.
- GlobalData (2013). Epilepsy – Italy Drug Forecast and Market Analysis to 2022. GDHC1041CFR.
- GlobalData (2013). Epilepsy – Spain Drug Forecast and Market Analysis to 2022. GDHC1042CFR.
- GlobalData (2013). Epilepsy – Japan Drug Forecast and Market Analysis to 2022. GDHC1044CFR.
- GlobalData (2013). Epilepsy – China Drug Forecast and Market Analysis to 2022. GDHC1046CFR.
- GlobalData (2013). Epilepsy – India Drug Forecast and Market Analysis to 2022. GDHC1045CFR.
• GlobalData (2013). Keppra (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1061DFR.

• GlobalData (2013). Lamictal (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1062DFR.

• GlobalData (2013). Lyrica (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1063DFR.

• GlobalData (2013). Vimpat (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1064DFR.

• GlobalData (2013). Zonegran (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1065DFR.

• GlobalData (2013). Banzel/Inovelon (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1066DFR.

• GlobalData (2013). Trobalt/Potiga (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1067DFR.

• GlobalData (2013). Zebinix (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1068DFR.

• GlobalData (2013). Fycompa (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1069DFR.

• GlobalData (2013). Ganaxolone (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1071DFR.

• GlobalData (2013). VX-765 (Epilepsy) – Forecast and Market Analysis to 2022. GDHC1072DFR.

• GlobalData (2013). Epilepsy – Current and Future Players. GDHC1005FPR
9.8 About GlobalData

GlobalData is a leading global provider of business intelligence in the Healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports, and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, Boston, London, India, and Singapore.

9.10 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.